Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl) amino]-3-pyridinyl] -4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide

Journal of Medicinal Chemistry

Volumn 45, Issue 22, 2002, Pages 4913-4922

  Owa, Takashi ^a   Yokoi, Akira ^a   Yamazaki, Kanami ^b   Yoshimatsu, Kentaro ^a   Yamori, Takao ^b   Nagasu, Takeshi ^a  

^a EISAI CO LTD   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INDISULAM; N (3 CHLORO 7 INDOLYL) 4 METHOXYBENZENESULFONAMIDE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NAVELBINE; NSC 641105; NSC 642599; NSC 643599; NSC 647959; NSC 676553; NSC 676569; NSC 676571; NSC 687773; NSC 687776; NSC 687778; NSC 687779; NSC 687780; PACLITAXEL; SULFONAMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ALGORITHMS; AMINOPHENOLS; ANTINEOPLASTIC AGENTS; BIOPOLYMERS; CELL CYCLE; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRANSCRIPTION, GENETIC; TUBULIN; TUMOR CELLS, CULTURED;

EID: 0037168033     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0201060     Document Type: Article

References (53)

1. Lander, E. S.; Linton, L. M.; Birren, B.; Nusbaum, C.; Zody, M. C.; et al. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860-921.
2. Venter, J. C.; Adams, M. D.; Myers, E. W.; Li, P. W.; Mural, R. J.; et al. The sequence of the human genome. Science 2001, 291, 1304-1351.
3. Scherf, U.; Ross, D. T.; Waltham, M.; Smith, L. H.; Lee, J. K.; et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 2000, 24, 236-244.
4. (a) Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
5. (b) Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; et al. Feasibility of a highflux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
6. Ramaswamy, S.; Tamayo, P.; Rifkin, R.; Mukherjee, S.; Yeang, C. H.; et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 15149-15154.
7. Su, A. I.; Welsh, J. B.; Sapinoso, L. M.; Kern, S. G.; Dimitrov, P.; et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 2001, 61, 7388-7393.
8. Zimmermann, J.; Erdmann, D.; Lalande, I.; Grossenbacher, R.; Noorani, M.; et al. Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1. Oncogene 2000, 19, 2913-2920.
9. Kudoh, K.; Ramanna, M.; Ravatn, R.; Elkahloun, A. G.; Bittner, M. L.; et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 2000, 60, 4161-4166.
10. Martinez, E. J.; Corey, E. J.; Owa, T. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem. Biol. 2001, 8, 1151-1160.
11. Rabow, A. A.; Shoemaker, R. H.; Sausville, E. A.; Covell, D. G. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J. Med. Chem. 2002, 45, 818-840.
12. (a) Dan, S.; Tsunoda, T.; Kitahara, O.; Yanagawa, R.; Zembutsu, H.; et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 2002, 62, 1139-1147.
13. (b) Yamori, T.; Matsunaga, A.; Sato, S.; Yamazaki, K.; Komi, A.; et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res. 1999, 59, 4042-4049.
14. (c) Naasani, I.; Seimiya, H.; Yamori, T.; Tsuruo, T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res. 1999, 59, 4004-4011.
15. Lockhart, D. J.; Dong, H.; Byrne, M. C.; Follettie, M. T.; Gallo, M. V.; et al. Expression monitoring by hybridization to highdensity oligonucleotide arrays. Nat. Biotechnol. 1996, 14, 1675-1680.
16. Yoshino, H.; Ueda, N.; Niijima, J.; Sugumi, H.; Kotake, Y.; et al. Novel sulfonamides as potential, systemically active antitumor agents. J. Med. Chem. 1992, 35, 2496-2497.
17. Owa, T.; Okauchi, T.; Yoshimatsu, K.; Sugi, N. H.; Ozawa, Y.; et al. A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 1223-1226.
18. Yoshimatsu, K.; Yamaguchi, A.; Yoshino, H.; Koyanagi, N.; Kitoh, K. Mechanism of action of E7010: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 1997, 57, 3208-3213.
19. Koyanagi, N.; Nagasu, T.; Fujita, F.; Watanabe, T.; Tsukahara, K.; et al. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res. 1994, 54, 1702-1706.
20. Yamamoto, K.; Noda, K.; Yoshimura, A.; Fukuoka, M.; Furuse, K.; et al. Phase I study of E7010. Cancer Chemother. Pharmacol. 1998, 42, 127-134.
21. Owa, T.; Yoshino, H.; Okauchi, T.; Yoshimatsu, K.; Ozawa, Y.; et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem. 1999, 42, 3789-3799.
22. Owa, T.; Nagasu, T. Novel sulphonamide derivatives for the treatment of cancer. Expert Opin. Ther. Pat. 2000, 10, 1725-1740.
23. Ozawa, Y.; Sugi, N. H.; Nagasu, T.; Owa, T.; Watanabe, T.; et al. E7070, a novel sulfonamide agent with potent antitumor activity in vitro and in vivo. Eur. J. Cancer 2001, 37, 2275-2282.
24. Watanabe, T.; Sugi, N.; Ozawa, Y.; Owa, T.; Nagasu, T.; et al. A novel antitumor agent ER-35744, targeting G1 phase. III. Studies of mechanism of action. Proc. Am. Assoc. Cancer Res. 1996, 37, A2667, 391.
25. Fukuoka, K.; Usuda, J.; Iwamoto, Y.; Fukumoto, H.; Nakamura, T.; et al. Mechanism of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest. New Drugs 2001, 19, 219-227.
26. Owa, T.; Yoshino, H.; Yoshimatsu, K.; Nagasu, T. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr. Med. Chem. 2001, 8, 1487-1503.
27. Dittrich, C.; Dumez, H.; Calvert, H.; Hanauske, A. R.; Ravic, M.; et al. Phase I and pharmacokinetic study of E7070 in patients with solid tumors as single iv infusion, weekly x 4, q 6 weeks. Proc. Am. Assoc. Cancer Res. 2000, 41, A3875, 609.
28. Droz, J. P.; Roche, H.; Zanetta, S.; Terret, C.; Blay, J. Y.; et al. Phase I trial of five-days continuous infusion E7070 [N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide] in patients (pts) with solid tumors. Proc. Am. Assoc. Cancer Res. 2000, 41, A3876, 609.
29. (a) Punt, C. J. A.; Fumoleau, P.; Walle, B. V. D.; Deporte-Fety, R.; Bourcier, C.; et al. Phase I and pharmacokinetic (PK) study of E7070, a novel sulphonamide, given daily × 5 every 3 weeks as a 1-hour intravenous infusion in patients (pts) with advanced solid tumors. Proc. Am. Assoc. Cancer Res. 2000, 41, A3877, 609.
30. Punt, C. J.; Fumoleau, P.; van de Walle, B.; Faber, M. N.; Ravic, M.; et al. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann. Oncol. 2001, 12, 1289-1293.
31. Raymond, E.; ten Bokkel-Huinink, W. W.; Taieb, J.; Beijnen, J. H.; Mekhaldi, S.; et al. Phase I and pharmacokinetic (PK) study of E7070, a new chloroindolylsulfonamide, given as a 1-hour infusion every 3 weeks in patients (pts) with advanced solid tumors. Proc. Am. Assoc. Cancer Res. 2000, 41, A3889, 611.
32. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
33. Yokoi, A.; Kuromitsu, J.; Kawai, T.; Nagasu, T.; Sugi, N. H.; et al. Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Mol. Cancer Ther. 2002, 1, 275-286.
34. Rödicker, F.; Stiewe, T.; Zimmermann, S.; Pützer, B. M. Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res. 2001, 61, 7052-7055.
35. Ben-Ze'ev, A.; Farmer, S. R.; Penman, S. Mechanisms of regulating tubulin synthesis in cultured mammalian cells. Cell 1979, 17, 319-325.
36. Rosania, G. R.; Chang, Y.-T.; Perez, O.; Sutherlin, D.; Dong, H.; et al. Myoseverin, a microtubule-binding molecule with novel cellular effects. Nat. Biotechnol. 2000, 18, 304-308.
37. Pettit, G. R.; Rhodes, M. R. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des. 1998, 13, 183-191.
38. Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga, Y.; et al. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J. Med. Chem. 1998, 41, 3022-3032.
39. Wang, L.; Woods, K. W.; Li, Q.; Barr, K. J.; McCroskey, R. W.; et al. Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J. Med. Chem. 2002, 45, 1697-1711.
40. Adams, J.; Elliott, P. J. New agents in cancer clinical trials. Oncogene 2000, 19, 6687-6692.
41. Beauregard, D. A.; Hill, S. A.; Chaplin, D. J.; Brindle, K. M. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res. 2001, 61, 6811-6815.
42. (a) Supuran, C. T.; Scozzafava, A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Pat. 2000, 10, 575-600.
43. Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Synthesis of N-morpholyl-thiocarbonyl-sulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV. Bioorg. Med. Chem. Lett. 2000, 10, 1117-1120.
44. Supuran, C. T.; Briganti, F.; Tilli, S.; Chegwidden, W. R.; Scozzafava, A. Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? Bioorg. Med. Chem. 2001, 9, 703-714.
45. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
46. Stockwell, B. R.; Hardwick, J. S.; Tong, J. K.; Schreiber, S. L. Chemical genetic and genomic approaches reveal a role for copper in specific gene activation. J. Am. Chem. Soc. 1999, 121, 10662-10663.
47. Foiani, M.; Lucchini, G.; Plevani, P. The DNA polymerase alphaprimase complex couples DNA replication, cell-cycle progression and DNA damage response. Trends Biochem. Sci. 1997, 22, 424-427.
48. Nigg, E. A. Cyclin-dependent kinase 7: at the cross-roads of transcription, DNA repair and cell cycle control? Curr. Opin. Cell Biol. 1996, 8, 312-317.
49. Yankulov, K. Y.; Bentley, D. L. Regulation of CDK7 substrate specificity by MAT1 and TFIIH. EMBO J. 1997, 16, 1638-1646.
50. Araujo, S. J.; Tirode, F.; Coin, F.; Pospiech, H.; Syvaoja, J. E.; et al. Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes Dev. 2000, 14, 349-359.
51. Kawakami, T.; Furukawa, Y.; Sudo, K.; Saito, H.; Takami, S.; et al. Isolation and mapping of a human gene (PDCD2) that is highly homologous to Rp8, a rat gene associated with programmed cell death. Cytogenet. Cell Genet. 1995, 71, 41-43.
52. Nakashima, T.; Suzuki, I. Ring contraction of 3-hydroxyquinolines to oxindoles with hydrogen peroxide in acetic acid. Chem. Pharm. Bull. 1969, 17, 2293-2298.
53. Holland, G. F.; Funderburk, W. H.; Finger, K. F. Preparation and anticonvulsant activity of N-substituted benzenedisulfonamides. J. Med. Chem. 1963, 6, 307-312.